Anna Tomczyk

• Select Medical Holdings Corporation, a leading operator of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers, and Concentra Group Holdings Parent, Inc., a wholly owned subsidiary of Select Medical, in connection with Concentra’s IPO.
• 21Shares and ARK Invest on the launch of their first Bitcoin ETP
• 21Shares on the launch of their first Ethereum ETP 
• Aquestive Therapeutics, a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, in its US$75 million CMPO.
• Femasys Inc., a clinical-stage medical device company, in its initial public offering.
• The ad hoc group of secured and unsecured bondholders of Brazil’s largest domestic airline, GOL Linhas Aéreas Inteligentes S.A., in connection with its US$1.6 billion combined liability management and new capital financing transaction.
• TAG Holdings Limited in its SPAC business combination with AGBA Acquisition Limited 
• BioAtla, Inc. (Nasdaq: “BCAB”) in its US$189 million initial public offering (with J.P. Morgan, Jefferies and Credit Suisse acting as joint book-running managers).
• VIA optronics AG, a leading supplier of enhanced display solutions, in its US$93.75 million cross- border initial public offering and listing on the NYSE.
• Acacia Research Corporation (Nasdaq: "ACTG") in connection with its strategic partnership with Starboard Value, consisting of a financing providing Acacia with access to up to US$400 million of new capital for strategic investments and acquisitions.
• B&G Foods in connection with its registered public offering of US$550 million in aggregate principal amount of 5.25% senior notes due 2027.
• Zyla Life Sciences in its merger with Assertio Therapeutics, Inc.
• Sales Agents in multiple At-The-Market offerings by Inovio Pharmaceuticals, Inc., a clinical stage company developing active DNA immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.
• OraSure Technologies, Inc. in its US$95 million public offering of common stock.
• The underwriters in connection with Repro Med Systems, Inc. d/b/a KORU Medical Systems (Nasdaq: KRMD)’s US$25 million public offering of common stock.
• Cowen and Company, as underwriter, in the US$97 million initial public offering of Boston Omaha Corporation.
• Minerva Neurosciences Inc. in its US$32 million initial public offering.
• Piper Jaffray, as managing underwriter, in the US$40 million initial public offering of Tengion Inc.
• Cowen and Company, as lead underwriter, in a US$55 million follow-on offering for TherapeuticsMD, Inc.
• Cowen and Company, as lead underwriter, in US$15 million and US$30 million follow-on offerings for Trillium Therapeutics.
• Cowen and Company, as sales agent, in at-the-market offerings for Amicus Therapeutics, Boston Omaha Corporation, Kempharm Inc., and Trillium Therapeutics Inc.
• Stifel, Nicolaus & Company, as lead underwriter, in a US$30 million follow-on offering for TherapeuticsMD, Inc.
• RBC Capital Markets LLC, as lead underwriter, in a US$25 million follow-on offering for Kempharm Inc.
• RBC Capital Markets LLC, as sales agent, in an at-the-market offering for Kempharm Inc.
• The initial purchasers in a US$225 million offering of convertible senior notes for Amicus Therapeutics.
• Anterios Inc. on its sale to Allergan.
• A fishing supply company in its US$330 million high yield note offering.
• Rexnord Corporation, in its US$500 million high yield note offering.
• A mass customization conglomerate in its US$400 million senior note offering.
• The underwriters, including Credit Suisse, Deutsche Bank, Goldman Sachs, J.P. Morgan, Morgan Stanley, UBS and Wells Fargo, in follow-on offerings of common stock and preferred stock of numerous international shipping and oil & gas companies, including Baltic Trading, Box Ships, Costamare, Dryships, Excel Maritime, GasLog, Ocean Rig, Safe Bulkers and Scorpio Bulkers.
• Jefferies, on securities law aspects of its US$10 billion merger of equals with Leucadia National Corporation.

Includes matters handled at Dechert or prior to joining the firm.

• Capital Raising and Asset Monetization Strategies for Life Sciences Companies — 2025 Life Sciences Day, Philadelphia, PA (March 5, 2025)

• AI, Biotech Companies at Risk in Nasdaq’s Penny Stock Crackdown – Quoted, Bloomberg Law (August 22, 2024)